Can You Eventually Stop CIDP Treatment and Reach Remission?

Yes, it is possible for some people with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to eventually stop treatment and remain stable. While CIDP is a chronic condition, not every patient requires lifelong treatment with intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), or corticosteroids.

In CIDP, “remission” generally means that the active immune attack on your nerves has stopped and your condition is stable without ongoing medication. However, it does not necessarily mean a complete cure of all symptoms, as residual weakness or numbness from prior nerve damage may remain ^[1].

Studies looking at carefully selected, clinically stable patients have found that between 25% and 37% can eventually discontinue their maintenance therapy without experiencing a relapse ^[2][3][4]. However, these statistics apply to specific study populations over set periods, and a withdrawal trial is not appropriate for everyone. Tapering is a carefully planned process, not a sudden event.

The Goal: Finding the Minimum Effective Dose

The 2021 European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) guidelines recommend that CIDP maintenance treatments be highly individualized ^[5][6]. The goal is to find your minimum effective dose—the lowest amount of medication needed to prevent your symptoms from worsening.

Because CIDP disease activity can fluctuate or naturally decline over time, guidelines suggest that if you have been clinically stable on a treatment for 6 to 12 months, your neurologist may consider cautiously testing whether that dose is still necessary ^[6][7].

For patients requiring very high doses of IVIG or steroids to remain stable, a specialist may sometimes discuss adding immunosuppressive medications to try and lower the primary dose ^[6][8]. However, this is not a routine step just to reduce IVIG; immunosuppressants carry significant risks, such as serious infections, and are only appropriate for selected patients under expert supervision.

How Tapering is Approached

Tapering means gradually reducing your medication under close medical supervision. Never change your dose or treatment schedule on your own.

• IVIG or SCIG: Tapering immunoglobulin usually involves either stretching out the time between your infusions or lowering the volume given. There is no single universal schedule. For example, one SCIG research study successfully tested a supervised taper by dropping the dose to 90%, 75%, 50%, 25%, and then 0% every 12 weeks, as long as the patient did not worsen ^[3]. Your neurologist will tailor a schedule specific to your body weight, formulation, and medical history.
• Corticosteroids: Steroids might offer prolonged periods of stability for some, but they must be tapered extremely slowly ^[9][10]. Because long-term steroid use suppresses the body’s natural cortisol production, abruptly stopping them can cause adrenal insufficiency or an adrenal crisis—a life-threatening medical emergency.

Tracking Your Progress: Complementing How You Feel

When lowering your dose, your daily experience—such as fatigue, pain, and how easily you can walk or button a shirt—is essential. However, daily energy levels naturally fluctuate. To complement your self-reporting, guidelines strongly recommend that your neurologist use standardized, objective tracking tools to confirm if a true relapse is happening ^[11][12].

Your neurologist will establish a “baseline” using a combination of these measurements:

• I-RODS (Inflammatory Rasch-built Overall Disability Scale): A questionnaire that scores your ability to perform specific daily activities ^[13].
• Grip Strength: Measured objectively with a hand-held squeezing device called a dynamometer ^[12].
• INCAT Disability Score: A clinical scale tracking your overall arm and leg function ^[14].
• MRC Sum Score: A standardized physical exam method used by doctors to test and grade the strength of specific muscle groups ^[12].

Using multiple standardized tools ensures that a temporary bad day isn’t mistaken for a relapse, and a true decline isn’t missed ^[12][15].

The Risks of Tapering and Having a Rescue Plan

The biggest risk of tapering is a CIDP relapse. A relapse is not just a minor inconvenience; it can cause significant weakness, an increased risk of falls, or further nerve damage.

Before attempting any dose reduction, you and your neurologist must agree on a rescue plan. While restabilizing is often highly successful—for example, one major IVIG withdrawal study (the PATH study) found that 91% of patients who deteriorated showed clinical improvement after their treatment was restarted—recovery can still take weeks or months, and complete immediate recovery is not guaranteed for everyone ^[16].

Your rescue plan should explicitly detail:

• What specific changes in your strength or mobility should prompt you to call the clinic.
• Who to contact if you experience rapid weakness, repeated falls, or difficulty swallowing or breathing (which requires urgent emergency care).
• How your rescue dose of IVIG or steroids will be rapidly authorized by insurance and scheduled, avoiding administrative delays if you need it quickly.

By combining careful monitoring with a solid rescue plan, you and your doctor can safely explore whether you can reduce your treatment burden or achieve long-term remission.